This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Source of effectiveness data
The effectiveness evidence was derived from a review of published studies.
Modelling
A state transition population model, which had been published, was constructed to trace the development of subregional populations. It considering births, deaths and the disease in question. Depression was defined as an episodic disorder with a high rate of remission and subsequent recurrence, and with excess mortality from unnatural causes (suicide). Persons not currently depressed became cases at an instantaneous transition rate (incidence, including recurrence). Persons with a depressive episode went back to being susceptible at determined remission rates. Cases were subject to the instantaneous case-fatality rate. Both susceptible persons and cases were subject to the general mortality rate. All data used to populate the model were derived from the literature. The time horizon of the model was lifetime. The cost-effectiveness of the treatment strategies was assessed as the difference between two scenarios. The first scenario was an epidemiological situation representing the natural history of depression (no intervention). The second scenario was an epidemiological situation reflecting the population-level impact of each specified intervention implemented for a 10-year period.
Outcomes assessed in the review
The outcomes assessed were: the prevalence of depression by age group and gender in each world region; the composite health state valuation (HSV) for an untreated depressive episode; the incidence and remission rates;
the case-fatality rates; and the efficacy of the interventions under evaluation. This was assessed in terms of improvement in HSV and remission rates, after considering the rates of coverage, adherence and partial response.
Study designs and other criteria for inclusion in the review
A systematic review of the literature does not appear to have been conducted. Most of the primary studies were clinical trials or of WHO data. Some information was obtained through personal communication.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Fifteen studies provided the evidence. 
Methods of combining primary studies

Investigation of differences between primary studies
Results of the review
The prevalence of depression (rates per 1,000 population), according to age group, is reported here for Eur A (e.g. France, Norway) only. For males (females), the prevalence was: 0 (0) for the 0-to 4-year age group, 11 (11) for the 5-to 14-year age group, The weighted average HSV for an untreated depressive episode was 0.62 (where 1 equated to full health), giving 23% severe (HSV=0.24), 47% moderate (HSV=0.65) and 30% mild (HSV=0.86).
The rate of incidence was calculated from the estimates of 6 months as the mean duration of an untreated depressive episode.
The remission hazard rate was 2. This was calculated as the inverse of the untreated episode duration (i.e. 1/0.5 years).
The case-fatality rate was 9% for age groups between 15 and 45 years. This was reduced to 3% for age groups over 45 years.
No excess risk of mortality from natural causes was attributed.
The coverage rates were 50%.
The rates of adherence ranged from 60% for strategy 1 (older antidepressants) to 75% for strategy 7 (proactive collaborative care with newer antidepressants).
The rate of partial response ranged from 15 to 20%.
The improvement in HSV was 4.5, 5, 5.8, 6.3, 6.3, 7.3 and 7.3%, respectively, with programmes 1 to 7.
The range of improvement in remission rates was: 9 to 10.5% for strategy 1, 9.5 to 11% for strategy 2, 7 to 8.8% for strategy 3,
Synthesis of costs and benefits
Average and incremental cost-effectiveness ratios were calculated to combine the costs and benefits of the interventions under evaluation.
The most cost-effective strategy (with a lower average cost-effectiveness ratio) in all sub-regions was that of older antidepressants (strategy 1). The average cost per DALY averted was: The incremental analysis showed that the most cost-effective single intervention was therapy with older antidepressants, while the most cost-effective combined intervention was strategy 6 (proactive collaborative care with older antidepressants). The incremental cost per DALY averted for strategy 6 was I$1,650 to I$1,850 in high-mortality developing sub-regions, I$2,000 to I$3,000 in low-mortality developing sub-regions, and I$2,300 to I$14,000 in developed sub-regions.
In all sub-regions, with the exception of the lowest-income sub-regions, the incremental cost per DALY averted of strategy 6 was considerably less than the average yearly income per capita, which was an international threshold value proposed for accepting an intervention as very cost-effective.
The sensitivity analyses showed that variations in the discount rate altered the cost-effectiveness ratio by 14% and -11%.
The removal of age-weighting resulted in an increase of 19 to 34% in the average cost-effectiveness ratios.
The best-case scenario lowered the average cost per DALY averted by 50 to 60%. The worst-case scenario led to substantial increases in the average and incremental cost-effectiveness ratios.
The probabilistic sensitivity analysis (run only for SeAs D) showed that, when resources were limited, older antidepressants were the most cost-effective strategy. More resource-consuming interventions could only be affordable with higher budgets.
